Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

ACR Leaders Discuss Rheumatology Medications at Medicare Drug Price Negotiation Town Hall

From the College  |  May 2, 2025

On April 30, Rebecca Shepherd, MD, MBA, and Amanda Myers, MD, represented rheumatology in a live town hall on the Medicare Drug Price Negotiation Program hosted by the Centers for Medicare & Medicaid Services (CMS). A transcript of the town hall will soon be posted on the CMS website.

In January, the CMS released the names of the 15 drugs included in the second round of negotiations. The prices for these drugs will be released later this year. As such, the CMS organized the town hall to seek insights on the value of these drugs. Specifically, presenters were asked to comment on:

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
  • The clinical benefits of selected drugs compared to therapeutic alternatives;
  • How the drugs address unmet patient needs;
  • The impact of these drugs on specific populations; and
  • Prescribing experiences and clinical considerations for treatment.

Dr. Myers’s presentation focused on Otezla (apremilast) and Dr. Shepherd’s focused on both Ofev (nintedanib) and Otezla. In particular, Dr. Myers highlighted how Otezla has provided tremendous benefits for patients with Behcet’s, plaque psoriasis and psoriatic arthritis, due to its oral delivery, lack of negative interactions with biologics and mild side effects.

Dr. Shepherd further highlighted that because Otezla is not a biologic, it does not require costly monitoring of blood counts and liver function tests to ensure patient safety and efficacy. She also discussed how the drug was instrumental in the treatment of a patient with severe psoriasis, allowing him to quickly return to his construction job. 

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In addition, Dr. Shepherd spoke on the significant evolution in patient care brought on by Ofev, namely for patients with systematic sclerosis, interstitial lung disease and idiopathic pulmonary fibrosis. She presented a distinct “before and after Ofev” landscape showing how patients with these diseases who are treated with the drug have experienced slowed loss of lung volume, reduced mortality and significantly lower likelihood of acute flares.

Both Dr. Myers, a former ACR Board of Directors member and current member of the Government Affairs Committee, and Dr. Shepherd, former chair of the ACR’s Insurance Subcommittee and current member of the Government Affairs Committee, expertly represented rheumatology and gave a strong case for the value that these drugs have brought to patient care. The ACR was proud to be represented by them and is always on the lookout for ways in which members can use their knowledge and expertise to advocate for the specialty.

The ACR is also steadfastly committed to ensuring that the voice of rheumatology is well-represented in the Medicare Drug Price Negotiation Program, that the drugs selected for negotiation adequately represent what rheumatologists are experiencing in the field and that these drugs are adequately priced.

For further information on the program, email the ACR advocacy team at [email protected] or contact the CMS at [email protected]. The ACR advocacy team will monitor the implementation of the program and other provisions of the IRA and serve as an educational resource for members on its impact on rheumatology.

Share: 

Filed under:InsuranceLegislation & Advocacy Tagged with:Advocacydrug pricesMedicare Drug Price Negotiation

Related Articles

    CMS to Host Town Halls on Medicare Drug Price Negotiation Program

    February 22, 2025

    These events will provide a critical opportunity for patients, caregivers, patient organizations, clinicians and researchers to offer input on the drugs selected for the second cycle of negotiations.

    ACR Insurance Subcommittee Chair Encourages Member Engagement

    January 20, 2022

    Rheumatology practices have a voice in payer advocacy through the Insurance Subcommittee of the ACR’s Committee on Rheumatologic Care.

    Medicare Bills Under the Magnifying Glass

    December 1, 2009

    What you need to know about the Recovery Audit Contractor program

    A Look Back at 2024 Regulatory Developments

    January 6, 2025

    In 2024, key federal healthcare regulations and policy developments—related to health insurance, privacy protections, reimbursement, biosimilar use and more—shaped the landscape of the practice of rheumatology in several important ways.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences